Plain-English translation of NCT07314060 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new injectable medication called TQH2929 to see if it can safely and effectively help people during severe flare-ups of generalized pustular psoriasis—a rare, serious skin condition where the body breaks out in widespread pustules (small, pus-filled bumps). Researchers want to understand whether this medication works better than a placebo (an inactive injection) and what side effects it might cause.
Generalized pustular psoriasis is a rare but potentially life-threatening skin disease, and current treatment options are limited. This trial exists to see if this new medication could offer patients a faster, safer way to control severe flare-ups.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous injection (given through a vein in your arm) of either the new medication or a placebo—you and the research team won't know which one you're receiving until the study ends. The study involves visits to a hospital or clinic where researchers will monitor your skin, check your overall health, and watch for any side effects. You'll need to be willing to use contraception if you are a woman of childbearing age, both during the study and for 6 months afterward.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China